| 1 |
35144131 | Targeted delivery of cancer drug paclitaxel to chordomas tumor cells via an RNA nanoparticle harboring an EGFR aptamer. | 2022 Apr |
1 |
| 2 |
35372004 | Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer. | 2022 |
1 |
| 3 |
35597872 | Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase. | 2022 May 21 |
7 |
| 4 |
33183015 | A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report. | 2021 Jun |
1 |
| 5 |
33235314 | Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. | 2021 Feb |
2 |
| 6 |
33721913 | Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma. | 2021 Sep |
3 |
| 7 |
34023418 | GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling. | 2021 Aug 28 |
1 |
| 8 |
34026617 | Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. | 2021 |
1 |
| 9 |
34046939 | CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR. | 2021 Dec |
4 |
| 10 |
34256895 | Identifying prognostic factors associated with overall survival in second-line paclitaxel plus ramucirumab treated human epidermal growth factor receptor 2-negative advanced/recurrent gastric cancer. | 2021 Jul 1 |
1 |
| 11 |
34479917 | Paclitaxel Impedes EGFR-mutated PC9 Cell Growth via Reactive Oxygen Species-mediated DNA Damage and EGFR/PI3K/AKT/mTOR Signaling Pathway Suppression. | 2021 Sep-Oct |
5 |
| 12 |
31856423 | Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy. | 2020 May |
1 |
| 13 |
32083171 | Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. | 2020 Feb |
4 |
| 14 |
32440910 | EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer. | 2020 May 21 |
1 |
| 15 |
32683880 | Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report. | 2020 Spring |
1 |
| 16 |
32720079 | Correction to: EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer. | 2020 Jul 27 |
1 |
| 17 |
32911509 | The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype. | 2020 |
1 |
| 18 |
30660004 | Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. | 2019 Mar 1 |
10 |
| 19 |
30662353 | Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway. | 2019 |
2 |
| 20 |
31146485 | In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus. | 2019 May 29 |
2 |
| 21 |
31401198 | Anti-EGFR antibody conjugated thiol chitosan-layered gold nanoshells for dual-modal imaging-guided cancer combination therapy. | 2019 Oct |
1 |
| 22 |
31477168 | A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). | 2019 Sep 2 |
1 |
| 23 |
31579626 | Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer. | 2019 |
1 |
| 24 |
31762748 | The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. | 2019 Sep-Dec |
1 |
| 25 |
31772161 | Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. | 2019 Nov 26 |
2 |
| 26 |
29411964 | Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy. | 2018 Mar 7 |
8 |
| 27 |
29874151 | Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. | 2018 May |
2 |
| 28 |
29909520 | Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer. | 2018 Sep |
1 |
| 29 |
30061586 | Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment. | 2018 Aug |
5 |
| 30 |
30254439 | Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein. | 2018 |
4 |
| 31 |
30307008 | Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis. | 2018 Nov 7 |
3 |
| 32 |
30388386 | Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. | 2018 Nov |
3 |
| 33 |
30408068 | Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities. | 2018 |
7 |
| 34 |
27435393 | Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder. | 2017 Jan 15 |
1 |
| 35 |
28212993 | Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. | 2017 Feb |
1 |
| 36 |
28253574 | [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer]. | 2017 Feb 25 |
4 |
| 37 |
28538405 | Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report. | 2017 May |
1 |
| 38 |
28852020 | Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. | 2017 Aug 29 |
2 |
| 39 |
31305693 | Erratum: Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report: Erratum. | 2017 Jul |
1 |
| 40 |
26338546 | Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. | 2016 Sep |
2 |
| 41 |
26709987 | Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. | 2016 Mar 15 |
1 |
| 42 |
26799187 | p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. | 2016 Feb 16 |
5 |
| 43 |
27100344 | Anticancer activity of drug conjugates in head and neck cancer cells. | 2016 Jun 1 |
1 |
| 44 |
24670093 | EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation. | 2015 |
2 |
| 45 |
25370413 | In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines. | 2015 Jan |
3 |
| 46 |
25553650 | A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). | 2015 Feb |
1 |
| 47 |
25583261 | BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. | 2015 Jan 13 |
1 |
| 48 |
25684511 | Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel. | 2015 |
1 |
| 49 |
25998561 | A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo. | 2015 Sep 18 |
2 |
| 50 |
26622855 | Paclitaxel induces apoptosis and reduces proliferation by targeting epidermal growth factor receptor signaling pathway in oral cavity squamous cell carcinoma. | 2015 Oct |
2 |